Clinical Research Details
Title:
A Randomized Phase III Trial of Cisplatin Plus Paclitaxel With and Without NCI-Supplied Bevacizumab (NSC #704865, IND #7921) Versus the Non-Platinum Doublet Topotecan Plus Paclitaxel With and Without NCI-Supplied Bevacizumab in Stage IVB, Recurrent or Persistent Carcinoma of the Cervix
Purpose:
The purpose of this study is to determine whether the addition of bevacizumab to chemotherapy improves overall survival and to determine if a regimen involving paclitaxel and topotecan improves overall survival in comparison to a regimen involving cisplatin and paclitaxel. Another purpose of this study is to determine and compare the frequency and severity of adverse events for the regimens administered in this study
Study Number:
201996071509
Number of Patients:
450
Elgibility:
Women must have primary stage IVB, recurrent or persistent squamous cell carcinoma, adenosquamous carcinoma or adenocarcinoma of the cervix, which is not amenable to curative treatment with surgery and/or radiation therapy.
Treatment:
Participants will receive one of four different treatments. Group 1 will receive two different drugs over one or two days every three weeks. Group 2 will receive three different drugs over one or two days every three weeks. Group 3 will receive two different drugs over one - three days every three weeks. Group 4 will receive three different drugs over one - three days every three weeks.
Principal Investigator:
Enrollment Phone:
(708) 327-3222